Rodman & Renshaw Begins Coverage on Jasper Therapeutics (NASDAQ:JSPR)

Rodman & Renshaw began coverage on shares of Jasper Therapeutics (NASDAQ:JSPR) in a research report issued to clients and investors on Tuesday, Marketbeat reports. The brokerage set a “buy” rating and a $17.00 price target on the stock.

A number of other brokerages have also weighed in on JSPR. BTIG Research dropped their price objective on Jasper Therapeutics from $20.00 to $7.00 and set a “buy” rating on the stock in a report on Monday, September 22nd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Jasper Therapeutics in a research note on Wednesday, October 8th. Evercore ISI reduced their target price on Jasper Therapeutics from $20.00 to $14.00 and set an “outperform” rating on the stock in a report on Monday, September 22nd. Finally, JMP Securities cut their target price on shares of Jasper Therapeutics from $12.00 to $6.00 and set a “market outperform” rating on the stock in a research note on Monday, September 22nd. Seven investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $19.88.

Jasper Therapeutics Stock Performance

Shares of JSPR stock traded up $0.07 during mid-day trading on Tuesday, hitting $1.55. 280,475 shares of the stock were exchanged, compared to its average volume of 1,559,176. The stock’s fifty day simple moving average is $1.77 and its two-hundred day simple moving average is $2.54. Jasper Therapeutics has a 12-month low of $1.39 and a 12-month high of $7.19. The stock has a market capitalization of $43.23 million, a price-to-earnings ratio of -0.26 and a beta of 3.07.

Jasper Therapeutics (NASDAQ:JSPR) last issued its quarterly earnings results on Monday, November 10th. The company reported ($1.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.01) by ($0.12). On average, research analysts expect that Jasper Therapeutics will post -4.47 earnings per share for the current fiscal year.

Institutional Trading of Jasper Therapeutics

Several large investors have recently added to or reduced their stakes in JSPR. Acadian Asset Management LLC bought a new stake in shares of Jasper Therapeutics during the first quarter valued at about $46,000. Marex Group plc acquired a new stake in shares of Jasper Therapeutics during the second quarter worth $74,000. Engineers Gate Manager LP purchased a new stake in Jasper Therapeutics during the second quarter valued at about $78,000. Voleon Capital Management LP purchased a new position in Jasper Therapeutics during the 3rd quarter worth approximately $50,000. Finally, Goldman Sachs Group Inc. grew its holdings in shares of Jasper Therapeutics by 11.2% during the first quarter. Goldman Sachs Group Inc. now owns 233,758 shares of the company’s stock valued at $1,005,000 after buying an additional 23,453 shares in the last quarter. 79.85% of the stock is currently owned by institutional investors and hedge funds.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc (NASDAQ: JSPR) is a clinical-stage biopharmaceutical company focused on translating advances in immunobiology into therapies for serious and rare diseases with unmet medical needs. The company’s research and development efforts center on engineered biologics and cell-based approaches designed to address complications in hematologic conditions and improve outcomes in transplant medicine.

Central to Jasper’s pipeline is JSP191, a monoclonal antibody targeting the CD117 receptor, which is being evaluated to enhance donor hematopoietic stem cell engraftment in patients undergoing stem cell transplantation.